GlassScriptPhysician profile
Shital Patel
NPI 1639498181
$1,580.76
in general payments reported to CMS, 2019-2025
23 companies · $697 in 2025
The $697 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $17.22 · 2022: $100 · 2023: $233 · 2024: $404 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,334.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $410.47 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $146.38 | 2019-2020 | |
| Novo Nordisk INC | $137.50 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $127.84 | 2022-2025 | Airsupra, Tezspire, Fasenra |
| Phathom Pharmaceuticals, INC. | $98.27 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.02 | 2024-2025 | Caplyta |
| Regeneron Healthcare Solutions, INC. | $70.37 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.45 | 2024 | Jardiance, Synjardy |
| Ars Pharmaceuticals Operations, INC. | $58.24 | 2025 | Neffy |
| Bayer Healthcare Pharmaceuticals INC. | $51.34 | 2025 | |
| Abbott Laboratories | $47.81 | 2024 | Eterna |
| Janssen Pharmaceuticals, INC | $41.05 | 2023-2024 | Spravato |
| Lilly USA, LLC | $36.18 | 2023-2025 | Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $31.68 | 2025 | Zoryve |
| Genzyme Corporation | $25.68 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $23.94 | 2023 | Immunocap |
| Dexcom, INC. | $22.16 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $21.82 | 2023 | |
| Inspire Medical Systems, INC. | $20.95 | 2025 | Inspire |
| Alk-Abello, INC | $19.00 | 2025 | Grastek, Ragwitek, Odactra |
| Kaleo, INC. | $15.31 | 2022 | |
| Sumitomo Pharma America, INC. | $15.29 | 2023 | Gemtesa |
| Ionis Pharmaceuticals, INC. | $15.01 | 2025 | Dawnzera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shital Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.